Menu
Recruiting NCT05635877

Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients

Phase IV Interventional Frailty Esmolol Myocardial Injury

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Esmolol, Placebo Comparator: Placebo Comparator:normal saline(0.9%).
Who it may be relevant to
Registry conditions: Frailty, Esmolol, Myocardial Injury. Basic parameters: 65 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients:A Multicenter, Prospective, Double-blind, Randomized Controlled Study

Overview

This topic will focus on the following questions: 1. Part one: To clarify the relationship between preoperative frailty and myocardial injury (cTnT ≥0.03) after non-cardiac surgery in elderly patients; To further explore the predictive factors of myocardial injury after non-cardiac surgery (MINS) in elderly frail patients before operation. 2. Part Two: To explore the effect of low-dose esmolol on myocardial injury after non-cardiac surgery in frail elderly patients.

Detailed description

Esmol is a short-acting selective β-adrenergic receptor blocker, which is often used in patients with cardiovascular diseases or hypertension. It is also used to reduce stress response, control heart rate and reduce myocardial oxygen consumption during perioperative period to effectively protect cardiac function. However, the safety and efficacy of perioperative β-blockers are still controversial due to their possible effects on renal function. Several recent studies have shown that β-blockers reduce perioperative myocardial ischemia and may reduce the risk of perioperative myocardial infarction (PMI) and cardiovascular death in high-risk patients . The 2021 American College of Cardiology /American Heart Association (ACC/AHA )guidelines for coronary revascularization suggest that dose adjustment can optimize the clinical effects of β-blockers, thereby reducing adverse effects during treatment . In addition, several studies have found that continuous intraoperative infusion of low-dose esmolol (5-10μg/kg/min) can reduce intraoperative stress response and maintain hemodynamic stability. The meta-analysis of esmolol by Ollila A et al. found that esmolol has a promising application in the prevention of perioperative myocardial ischemia and serious complications associated with long-term ischemia. Does perioperative Esmolol reduce the incidence of myocardial injury after non-cardiac surgery (MINS)? The safety, outcome and benefit of perioperative esmolol in frail patients are still unclear. Therefore, this study intends to apply the appropriate dose of esmolol to prevent cardiovascular events in elderly frailty patients undergoing non-cardiac surgery, and explore the effect of low-dose esmolol on MINS in elderly frail patients, so as to provide feasible clinical measures for the safe outcome and rehabilitation of frail patients during perioperative period.

Interventions

  • Drug Esmolol
    The treatment group was given Esmolol 0.5mg/kg load and 10μg /kg/min continuous pump
  • Drug Placebo Comparator: Placebo Comparator:normal saline(0.9%)
    The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.

Primary outcome measures

  • incidence of Postoperative myocardial injury after non-cardiac surgery(MINS) [Time frame: incidence of MINS within 3 days after operation]
Secondary outcome measures (1)
  • the results of 30 days after surgery [Time frame: Outcomes at 30 days after operation were recorded]

Eligibility criteria

Inclusion criteria

  • Age ≥ 65 years;
  • ASA: ⅰ-ⅳ;
  • Modified frailty index (mFI) ≥ 0.21;
  • Patients undergoing non-cardiac surgery.

Exclusion criteria

  • Refuse to participate;
  • Expected hospital stay <3 days;
  • Preoperative β-blocker therapy;
  • History of myocardial infarction or coronary artery disease;
  • Preoperative bradycardia (heart rate \[HR\] < 50 bpm) or arrhythmia;
  • Significant cardiac insufficiency (i.e., pulmonary artery pressure >18 mm Hg, cardiac index ≤ 2.2 L/min/m 2);
  • Severe valvular heart disease;
  • Severe lung disease (e.g. asthma or chronic obstructive pulmonary disease);
  • Patients with perioperative troponin elevation due to nonischemic causes (e.g., sepsis, pulmonary embolism, arrhythmia);
  • The same patient can only be included once, regardless of whether the reason for the second operation is related to the first cause.

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Other

Study locations

China · 1 center
  • Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University — Jinan

Publications

  • Sun Y, Guo N, Zhang M, Liu M, Gao Z, Sun T, Gao X, Xu L, Zhang H, Wei C, Liu P, Liu Y, Zhang X, Guo Y, Chen L, Zhou Z, Su Z, Hu Y, Shi X, Huang L, Wang Y. Association between preoperative frailty and myocardial injury after noncardiac surgery in geriatric patients: study protocol for a prospective, multicentre, real-world observational, cohort trial. BMC Geriatr. 2024 Mar 19;24(1):271. doi: 10.118 PMID 38504166

Identifiers

NCT: NCT05635877 · 20221028YTsun

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗